Global Crohn's Disease Diagnostic and Therapeutic Market - Segmented by Type of Disease, Diagnosis, Treatment, and Geography - Growth, Trends, and Forecast (2018 - 2023)
|出版商||Mordor Intelligence LLP||商品編碼||391371|
|出版日期||內容資訊||英文 105 Pages
|克隆氏症診斷及治療的全球市場:成長，趨勢與預測(2017年∼2022年) Global Crohn's Disease Diagnostic and Therapeutic Market - Segmented by Type of Disease, Diagnosis, Treatment, and Geography - Growth, Trends, and Forecast (2018 - 2023)|
|出版日期: 2018年05月01日||內容資訊: 英文 105 Pages||
The global Crohn's disease diagnostic and therapeutic market is estimated to grow at a good CAGR during the forecast period. Crohn's disease (CD) is an inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from mouth to the anus. It is caused by a combination of environmental, immune, and bacterial factors, in genetically predisposed individuals.
It is estimated that around 1.6 million Americans have the inflammatory bowel disease (IBD). This number includes about 780,000 population are having Crohn's disease, and another 907,000 people are with ulcerative colitis. Research suggests that about six to 15 new cases of Crohn's disease are diagnosed per 100,000 people each year. People are most frequently diagnosed with Crohn's disease and ulcerative colitis in the late adolescence or in early adulthood, even though the diagnosis may happen at any age. Many population-based research studies have shown that Crohn's disease is somewhat more common in women than men, while ulcerative colitis is slightly more common in men than women. As the prevalence of the disease increases, it is expected to drive the Crohn's disease diagnostic and therapeutic market.
Also, the increasing demand for prompt diagnosis and multiple symptoms associated with the disease requiring individual therapeutic attention, are increasing the growth of the market.
Current costs for the treatment and diagnosis of Crohn's disease is high, due to the availability of several new therapeutic drugs and changes in the surgical treatment of the disease. For example, the total cost of Crohn's disease in the United States is around USD 3.6 billion every year, and the average yearly medical cost per patient is about USD 8,265, with more than one-third of that cost being medications. Biologic medications or drugs are usually expensive. Hospitalization accounted for 31.4% of the cost. On an average, people who have to be hospitalized for Crohn's disease are expected to spend about 5.8 days in the hospital. All these treatment cost issues are hindering the Crohn's diagnostic and therapeutic market. Also, as no specific treatment or drug is available in the market, and there is lack of awareness among the people coupled with symptom similarity with other gastrointestinal disease are hindering the market growth.
North America is dominating the Crohn's disease diagnostic and therapeutic market due to the increasing prevalence of Crohn's disease in the region. Asia-Pacific is expected to record a substantial growth in the forecast period.
This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
List not Exhaustive